Table 3.

Time course of gastrointestinal (GI) symptoms related to diagnosis, as well as immunosuppressive therapy before and after GI symptoms. A negative value indicates onset before diagnosis of MPA or GPA. Date of diagnosis was defined by start of immunosuppressive therapy (mostly corticosteroids).

Patient No.	First GPA or MPA Symptoms, Days from Diagnosis	First GI Symptoms, Days from Diagnosis	Approximate Duration of GI Symptoms, Days^*	Dose Pred/other Therapy at Onset of GI Symptoms	Additional Immune Therapy after GI Symptoms
1	−49	+81	79	30 mg/CYC oral	CYC IV, PE
2	−105	+14	31	60 mg/MP IV, CYC IV, PE	—
3	−200 (diagnosis of relapse)	+59	24	20 mg/CYC IV	—
4	−201	−12	9	0 mg/none	MP IV, Pred, CYC IV
5	−59	−52	57	0 mg/none	MP IV, Pred, CYC IV, PE
6	−49	+7	1	40 mg/CYC IV, PE	—
7	−48	0	43	0 mg/MP IV, CYC oral	PE
8	−8	−2	38	0 mg/none	Pred, CYC oral
9	−56	+26	15	20 mg/MP IV, CYC IV	RTX
10	−8	−8	14	0 mg/none	MP IV, Pred, CYC IV, RTX, PE
11	−249	+71	4	20 mg/CYC IV, PE, RTX	—
12	−17	+3	102	0 mg/MP IV	Pred, CYC IV, RTX, PE
13	−32	−2	53	0 mg/none	MP IV, RTX, PE
14	−10 (diagnosis of relapse)	+19	12	40 mg/RTX	—

↵* Duration of GI symptoms is approximated because some, but far from all, patients were operated on. CYC: cyclophosphamide; Pred: prednisolone; MP: methylprednisolone pulse; IV: intravenous; RTX: rituximab; PE: plasma exchange; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis.